253 related articles for article (PubMed ID: 29800728)
41. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
Rasmussen TA; Lewin SR
Curr Opin HIV AIDS; 2016 Jul; 11(4):394-401. PubMed ID: 26974532
[TBL] [Abstract][Full Text] [Related]
42. HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.
Dental C; Proust A; Ouellet M; Barat C; Tremblay MJ
J Immunol; 2017 Feb; 198(3):1229-1241. PubMed ID: 27994072
[TBL] [Abstract][Full Text] [Related]
43. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
44. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
45. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4
Fromentin R; DaFonseca S; Costiniuk CT; El-Far M; Procopio FA; Hecht FM; Hoh R; Deeks SG; Hazuda DJ; Lewin SR; Routy JP; Sékaly RP; Chomont N
Nat Commun; 2019 Feb; 10(1):814. PubMed ID: 30778080
[TBL] [Abstract][Full Text] [Related]
46. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
47. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
48. Reversal of Latency as Part of a Cure for HIV-1.
Rasmussen TA; Tolstrup M; Søgaard OS
Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
[TBL] [Abstract][Full Text] [Related]
49. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.
Beans EJ; Fournogerakis D; Gauntlett C; Heumann LV; Kramer R; Marsden MD; Murray D; Chun TW; Zack JA; Wender PA
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11698-703. PubMed ID: 23812750
[TBL] [Abstract][Full Text] [Related]
50. Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4
Cao S; Slack SD; Levy CN; Hughes SM; Jiang Y; Yogodzinski C; Roychoudhury P; Jerome KR; Schiffer JT; Hladik F; Woodrow KA
Sci Adv; 2019 Mar; 5(3):eaav6322. PubMed ID: 30944862
[TBL] [Abstract][Full Text] [Related]
51. HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells.
Chan CN; Trinité B; Lee CS; Mahajan S; Anand A; Wodarz D; Sabbaj S; Bansal A; Goepfert PA; Levy DN
Retrovirology; 2016 Jan; 13():1. PubMed ID: 26728316
[TBL] [Abstract][Full Text] [Related]
52. Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion.
Proust A; Barat C; Leboeuf M; Drouin J; Tremblay MJ
J Neuroinflammation; 2017 Dec; 14(1):242. PubMed ID: 29228979
[TBL] [Abstract][Full Text] [Related]
53. Diversity of small molecule HIV-1 latency reversing agents identified in low- and high-throughput small molecule screens.
Hashemi P; Sadowski I
Med Res Rev; 2020 May; 40(3):881-908. PubMed ID: 31608481
[TBL] [Abstract][Full Text] [Related]
54. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
55. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
Rochat MA; Schlaepfer E; Speck RF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
[TBL] [Abstract][Full Text] [Related]
56. Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products.
Richard K; Williams DE; de Silva ED; Brockman MA; Brumme ZL; Andersen RJ; Tietjen I
Viruses; 2018 Jun; 10(7):. PubMed ID: 29954099
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells.
Iordanskiy S; Van Duyne R; Sampey GC; Woodson CM; Fry K; Saifuddin M; Guo J; Wu Y; Romerio F; Kashanchi F
Virology; 2015 Nov; 485():1-15. PubMed ID: 26184775
[TBL] [Abstract][Full Text] [Related]
58. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
[TBL] [Abstract][Full Text] [Related]
59. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
[TBL] [Abstract][Full Text] [Related]
60. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
Bricker KM; Chahroudi A; Mavigner M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
